Pegaspargase
- Generic Name
- Pegaspargase
- Brand Names
- Oncaspar
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 130167-69-0
- Unique Ingredient Identifier
- 7D96IR0PPM
- Background
Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synt...
- Indication
Pegaspargase is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with 1) first-line acute lymphoblastic leukemia or 2) acute lymphoblastic leukemia and hypersensitivity to asparaginase.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Associated Therapies
- -
Optimization of Therapy in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
- Conditions
- Interventions
- Drug: RituximabProcedure: Cranial irradiationDrug: NelarabineDrug: IdarubicinDrug: PEG-AsparaginaseDrug: ImatinibDrug: FludarabineDrug: DexamethasoneDrug: CyclophosphamideDrug: VincristineDrug: MethotrexateProcedure: Stem cell transplantationDrug: MercaptopurineDrug: CytarabineDrug: VP16Drug: VindesineDrug: Daunorubicin (DNR)Drug: AdriamycinDrug: Prednisolone
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 1000
- Registration Number
- NCT02881086
- Locations
- 🇩🇪
University Hospital of Frankfurt (Main), Frankfurt (Main), Germany
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
- Conditions
- Interventions
- Drug: AzacitidineDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Hydrocortisone Sodium SuccinateOther: Laboratory Biomarker AnalysisDrug: LeucovorinDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseOther: Pharmacological StudyDrug: PrednisoloneDrug: ThioguanineDrug: VincristineDrug: Vincristine Sulfate
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 78
- Registration Number
- NCT02828358
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02825147
- Locations
- 🇨🇳
Shanghai Ruijin Hospital, Shanghai, China
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 171
- Registration Number
- NCT02723994
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Texas Childrens Hospital, Houston, Texas, United States
PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 35
- Registration Number
- NCT02705508
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Please Select, China
Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL
- Conditions
- Interventions
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 100
- Registration Number
- NCT02660762
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China
L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis
- Conditions
- Interventions
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT02631109
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 256
- Registration Number
- NCT02631239
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
- Conditions
- Interventions
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT02553460
- Locations
- 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Rady Children's Hospital and Health Center, San Diego, California, United States
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
- First Posted Date
- 2015-08-31
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Children's Mercy Hospital Kansas City
- Target Recruit Count
- 2
- Registration Number
- NCT02535806
- Locations
- 🇺🇸
Children's Mercy Hospital, Kansas City, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.